CTI BioPharma Corp. (CTIC)

CTI BioPharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Cash & Equivalents	24.21	30.42	65.45	40.39	31.14	36.44
Short-Term Investments	34.8	49.52	0	12.06	2.52	30.6
Cash & Cash Equivalents	59.01	79.94	65.45	52.45	33.67	67.04
Cash Growth	-39.10%	22.14%	24.78%	55.80%	-49.78%	55.12%
Receivables	22.96	15.39	0	0	0	13.68
Inventory	0.78	0.73	0	0	0	0
Other Current Assets	3.71	3.34	2.93	1.87	1.91	1.78
Total Current Assets	86.45	99.4	68.38	54.33	35.58	82.49
Property, Plant & Equipment	0	0	0.18	0.72	1.24	1.79
Goodwill and Intangibles	22.71	23.23	0	0	0	0
Other Long-Term Assets	3.11	3.3	3.88	3.2	9.47	5.55
Total Long-Term Assets	25.82	26.53	4.06	3.92	10.7	7.34
Total Assets	112.27	125.93	72.43	58.24	46.28	89.83
Accounts Payable	2.03	2.01	3.89	1.64	0	4.5
Current Debt	48.08	47.94	47.38	4.46	4.81	4.81
Other Current Liabilities	18.12	31.18	15.38	10.95	13.68	13.75
Total Current Liabilities	68.23	81.13	66.65	17.04	18.49	23.06
Long-Term Debt	68.37	61.13	0	0	4.46	9.27
Other Long-Term Liabilities	1.02	1.23	2.02	1.17	5.41	4.57
Total Long-Term Liabilities	69.39	62.37	2.02	1.17	9.86	13.84
Total Liabilities	137.62	143.5	68.67	18.21	28.35	36.89
Total Debt	116.46	109.08	47.38	4.46	9.27	14.08
Debt Growth	9.75%	130.22%	963.52%	-51.93%	-34.18%	0.43%
Common Stock	2,507	2,501	2,430	2,368	2,299	2,294
Retained Earnings	-2,532	-2,519	-2,426	-2,328	-2,276	-2,225
Comprehensive Income	-0.01	-0.04	0	0	0	-10.64
Shareholders' Equity	-25.35	-17.58	3.77	40.03	23.69	58.69
Net Cash / Debt	-57.44	-29.14	18.07	48	24.4	52.96
Net Cash / Debt Growth	-	-	-62.36%	96.71%	-53.93%	81.37%
Net Cash Per Share	-0.44	-0.25	0.20	0.67	0.42	0.94
Working Capital	18.23	18.26	1.73	37.29	17.09	59.44
Book Value Per Share	-0.19	-0.15	0.04	0.56	0.41	1.05

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).